Long-term reduction in IOP due to uneventful surgical procedures in PXG patients

Article

Pseudoexfoliation glaucoma (PXG) patients who underwent uneventful uneventful phacoemulsification, IOL implantation, and trabeculectomy experienced long-term lower IOP and required fewer medications during 10 years.

Pseudoexfoliation glaucoma (PXG) patients who underwent uneventful uneventful phacoemulsification, IOL implantation, and trabeculectomy experienced long-term lower IOP and required fewer medications during 10 years, claims a paper published in the Journal of Cataract and Refractive Surgery.

Dr Bradford J. Shingleton et al., Center for Eye Research and Education, Boston, Massachusetts, USA, performed a retrospective, comparative case series analysis on consecutive eyes with pseudoexfoliation glaucoma (PXG) that underwent uneventful combined phacoemulsification and trabeculectomy. Change in intraocular pressure (IOP), glaucoma medication requirements and logMAR corrected distance visual acuity was compared between the phaco-only group and the combined surgery group.

Mean IOP and glaucoma medication requirements significantly reduced when patients underwent combined surgery, compared to the phaco-only group. Reduction in mean postoperative IOP was more significant in eyes with a higher mean preoperative IOP. Of the eyes included in the combined-surgery group, 13.8% needed subsequent laser trabeculoplasty, glaucoma surgery or a combination of the two.

Combined surgical procedures lead to long-term reductions in IOP and glaucoma medication requirements, as well as fewer 1-day postoperative spikes.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.